RYBELSUS: Its is hard to find a place for it because there are SQ GLP-1 agonists with predictable absorption and other oral antidiabetics with greater experience of use

OZEMPIC: It is an alternative more effective compared to its analogues but with more adverse events and higher cost.

TOVEDESO: Due to the absence of comparative studies and assimilate data of its prodrug fesoterodine, it is considered desfesoterodine does not imply an improvement over other urinary antispasmodics for treatment of overactive bladder syndrome